Real-time Estimate
Cboe BZX
01:06:01 2024-05-22 pm EDT
|
5-day change
|
1st Jan Change
|
2.375
USD
|
+27.69%
|
|
+8.37%
|
+20.96%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
369.3
|
1,003
|
370.7
|
62
|
174.9
|
166.5
|
-
|
-
|
Enterprise Value (EV)
1 |
369.3
|
1,003
|
370.7
|
62
|
174.9
|
166.5
|
166.5
|
166.5
|
P/E ratio
|
-13.9
x
|
-32.7
x
|
-10.5
x
|
-1.84
x
|
-9.43
x
|
-37.2
x
|
372
x
|
-13.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
502
x
|
61.8
x
|
8.27
x
|
5.23
x
|
4.5
x
|
4.05
x
|
4.58
x
|
EV / Revenue
|
-
|
502
x
|
61.8
x
|
8.27
x
|
5.23
x
|
4.5
x
|
4.05
x
|
4.58
x
|
EV / EBITDA
|
-13,239,789
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-13.2
x
|
-35.2
x
|
-16.4
x
|
-1.77
x
|
-4.85
x
|
2.53
x
|
78.2
x
|
11
x
|
FCF Yield
|
-7.59%
|
-2.84%
|
-6.1%
|
-56.4%
|
-20.6%
|
39.6%
|
1.28%
|
9.07%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
61,956
|
82,857
|
86,214
|
86,625
|
88,327
|
89,530
|
-
|
-
|
Reference price
2 |
5.960
|
12.11
|
4.300
|
0.7157
|
1.980
|
1.860
|
1.860
|
1.860
|
Announcement Date
|
2/20/20
|
2/25/21
|
2/24/22
|
2/27/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
2
|
6
|
7.5
|
33.46
|
37.04
|
41.12
|
36.38
|
EBITDA
|
-27.89
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-28.88
|
-31.5
|
-35.07
|
-35.37
|
-12.99
|
-5.268
|
-4.48
|
-19.07
|
Operating Margin
|
-
|
-1,574.8%
|
-584.57%
|
-471.65%
|
-38.83%
|
-14.23%
|
-10.9%
|
-52.42%
|
Earnings before Tax (EBT)
1 |
-28.06
|
-29.7
|
-34.2
|
-33.64
|
-9.784
|
-2.191
|
-1.93
|
-15
|
Net income
1 |
-27.34
|
-29.7
|
-34.2
|
-33.69
|
-18.75
|
-4.578
|
-1.93
|
-15.2
|
Net margin
|
-
|
-1,484.9%
|
-570.05%
|
-449.25%
|
-56.05%
|
-12.36%
|
-4.7%
|
-41.78%
|
EPS
2 |
-0.4300
|
-0.3700
|
-0.4100
|
-0.3900
|
-0.2100
|
-0.0500
|
0.005000
|
-0.1350
|
Free Cash Flow
1 |
-28.04
|
-28.49
|
-22.63
|
-34.98
|
-36.06
|
65.89
|
2.13
|
15.1
|
FCF margin
|
-
|
-1,424.3%
|
-377.1%
|
-466.44%
|
-107.77%
|
177.91%
|
5.18%
|
41.51%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/20/20
|
2/25/21
|
2/24/22
|
2/27/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
6
|
-
|
-
|
-
|
-
|
7.5
|
-
|
-
|
-
|
33.46
|
2.559
|
2.492
|
2.492
|
30.54
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.333
|
-8.78
|
-9.996
|
-9.637
|
-12.21
|
-3.529
|
-10.13
|
-10.21
|
-10.63
|
17.98
|
-8.949
|
-7.6
|
-8.258
|
19.08
|
Operating Margin
|
-105.55%
|
-
|
-
|
-
|
-
|
-47.05%
|
-
|
-
|
-
|
53.75%
|
-349.71%
|
-304.89%
|
-331.31%
|
62.47%
|
Earnings before Tax (EBT)
1 |
-6.156
|
-8.645
|
-9.71
|
-9.144
|
-11.75
|
-3.034
|
-9.326
|
-9.325
|
-9.852
|
18.72
|
-7.264
|
-6.714
|
-7.11
|
20.12
|
Net income
1 |
-6.156
|
-8.645
|
-9.71
|
-9.144
|
-11.75
|
-3.092
|
-9.339
|
-9.276
|
-9.852
|
9.713
|
-7.267
|
-7.264
|
-7.695
|
18.87
|
Net margin
|
-102.6%
|
-
|
-
|
-
|
-
|
-41.23%
|
-
|
-
|
-
|
29.03%
|
-283.98%
|
-291.41%
|
-308.73%
|
61.78%
|
EPS
2 |
-0.0700
|
-0.1000
|
-0.1100
|
-0.1100
|
-0.1400
|
-0.0400
|
-0.1100
|
-0.1100
|
-0.1100
|
0.1100
|
-0.0800
|
-0.0800
|
-0.0850
|
0.2000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
2/24/22
|
5/16/22
|
8/4/22
|
11/14/22
|
2/27/23
|
5/15/23
|
8/7/23
|
11/7/23
|
3/5/24
|
5/20/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-28
|
-28.5
|
-22.6
|
-35
|
-36.1
|
65.9
|
2.13
|
15.1
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.16
|
0.17
|
0.29
|
0.48
|
0.17
|
0.19
|
0.19
|
0.19
|
Capex / Sales
|
-
|
8.3%
|
4.87%
|
6.36%
|
0.51%
|
0.51%
|
0.46%
|
0.52%
|
Announcement Date
|
2/20/20
|
2/25/21
|
2/24/22
|
2/27/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
1.86
USD Average target price
5
USD Spread / Average Target +168.82% Consensus |
1st Jan change
|
Capi.
|
---|
| +20.96% | 167M | | +58.67% | 55.07B | | -1.51% | 41.79B | | +44.36% | 40.22B | | -8.29% | 28.17B | | +12.14% | 26.28B | | -21.13% | 18.93B | | +6.80% | 13.03B | | +28.51% | 12.26B | | +26.27% | 12.21B |
Other Biotechnology & Medical Research
|